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Cognitive and neuroanatomical
impairments associated with chronic
exposure to levamisole-contaminated
cocaine
Matthias Vonmoos1, Sarah Hirsiger1, Katrin H. Preller 1, Lea M. Hulka1,2, Daniel Allemann3, Marcus Herdener2,
Markus R. Baumgartner4 and Boris B. Quednow 1,5
Abstract
Currently, levamisole is the most common cocaine adulterant worldwide and it is known to induce a variety of adverse
side effects. Animal studies and human case reports suggest potential neurotoxicity of the compound but neither
neuroanatomical nor cognitive effects of levamisole have been systematically investigated in cocaine users so far. We
examined cognitive performance and cortical structural differences between chronic cocaine users with low and high
recent exposure to levamisole objectively determined by quantitative toxicological hair analyses. In Study 1, we
compared 26 chronic cocaine users with low levamisole exposure (lowLevCU), 49 matched cocaine users with high
levamisole exposure (highLevCU), and 78 matched stimulant-naive controls regarding cognitive functioning employing
a comprehensive neuropsychological test battery. In Study 2, we investigated cortical thickness by use of T1-weighted
MRI in a subgroup of 12 lowLevCU, 17 highLevCU, and 38 stimulant-naive controls. In Study 1, both cocaine user groups
showed signiﬁcant impairments in the cognitive domains of attention and working memory as well as in the global
cognitive index. However, highLevCU showed signiﬁcantly worse executive functions compared to lowLevCU although
both groups did not differ in severity of cocaine consumption and other clinical dimensions. Study 2 revealed that
highLevCU, displayed reduced cortical thickness speciﬁcally in the middle frontal gyrus compared to both controls and
lowLevCU. Our results suggest that levamisole exposure during the last months in cocaine users is associated with
increased executive function impairments and pronounced thinning of the lateral prefrontal cortex. Consequently,
prevention and drug policy-making should aim to reduce levamisole contamination of street cocaine.
Introduction
The tetramisole enantiomer levamisole is used as a
veterinary anthelminthic that was also approved as an
adjuvant in colon cancer treatment in some countries
before it was withdrawn from the market in 2000 because
of its adverse side effects1. In 2004, the U.S. Drug Enfor-
cement Agency (DEA) initially detected levamisole as a
adulterant in cocaine seizures2. In the mobile drug-
checking program of Switzerland, levamisole was recog-
nized in 2008 for the ﬁrst time as an adulterant in street
cocaine. Measurements revealed that between 2009 and
2016, 50 to 70% of all cocaine specimens contained
levamisole (Fig. 1). Similar trends of extensive levamisole
contamination of street cocaine across the last decade
were shown for the US and for different European
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countries3,4. The recent drop of the levamisole prevalence
in Switzerland is a phenomenon that to our knowledge
has not been shown in other countries so far (Fig. 1). By
contrast, in October 2017, the DEA reported that 87% of
the seized and analyzed cocaine bricks contained leva-
misole.4 Thus, levamisole is currently the most common
cocaine adulterant in Europe and North America3,4.
The mixture of cocaine with other pharmacological
components (primarily prescription drugs and over-the-
counter agents, see Fig. 1) prior to being sold on the
streets lead to a decline of cocaine purity in the main
consumer markets of North America and Europe5. These
adulterants were generally added for two reasons. First,
they are available, cheap, have similar chemo-physical
properties (color, texture, melting point) and, thus,
increase the proﬁt of the drug dealer. Second, some
additives are supposed to enhance the psychoactive effects
of the drug by exerting additional pharmacological
effects1,6. In the case of levamisole, it was shown that the
compound itself has negligible effects on monoamine
transporters, but it was proposed that the mother com-
pound is metabolized—among others—to aminorex, a
psychostimulant agent that shows potent amphetamine-
like effects1,6,7. A drug discrimination study with rats
showed very recently that levamisole in fact potentiates
the subjective effects of cocaine when administered
concomitantly8.
Levamisole has a wide range of adverse side effects. In
recent years, an accumulating body of literature described
a clear linkage between levamisole-adulterated cocaine
use and the occurrence of neutropenia and agranulocy-
tosis, vasculitis, retiform purpura and other forms of skin
necrosis, vasculopathy, arthralgia, and leukoencephalo-
pathy1,9–11. Its potential neurotoxicity was ﬁrst reported
in dogs experimentally exposed to levamisole showing
disseminated perivascular cufﬁng with mononuclear cells
throughout the brain12. Since 1992, a number of case
reports suggested that the association between the
administration of levamisole (in cancer therapy or
through cocaine intake) and multifocal inﬂammatory
leukoencephalopathy is also apparent in humans1,9,13. In
sum and although exact data on the prevalence of toxicity
related to levamisole-adulterated cocaine abuse are
missing so far3, its wide distribution and potential neu-
rotoxicity have been classiﬁed a serious public health
concern worldwide11,14. Although it is important to better
understand the speciﬁc neuropsychiatric risks associated
with levamisole exposure1 no case–control study investi-
gating the neuropsychiatric risks of levamisole-
contaminated cocaine has been published yet.
Previously, we have shown that the intensity of cocaine
intake covaries with cognitive impairments in cocaine
users (CU), suggesting that the well-described cognitive
deﬁcits in this population are largely drug-induced but
Fig. 1 Additives in cocaine samples in Switzerland between 2004 and 2018. Lines indicate percent frequency of occurrence. Recruitment
periods of cocaine users for both studies are shaded in gray. The data were collected in mobile laboratories in Berne, Zurich, and Basel (total n= 771).
Data were provided by the Ofﬁce of the Cantonal Pharmacist, Health & Social Welfare Department State of Berne, Switzerland (Daniel Allemann,
Hans-Jörg Helmlin, and André Mürner). *Data only from the ﬁrst half-year 2018 (January–August)
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also potentially reversible15–17. In this context, we now
hypothesize that cocaine-related cognitive impairments
might not only derive from cocaine itself, but also from its
main adulterant levamisole. Thus, in Study 1, we com-
pared two CU groups with similar cocaine use severity but
with high (highLevCU) vs. low recent levamisole exposure
(lowLevCU) and a matched stimulant-naive control group
in their performance in a comprehensive neuropsycho-
logical test battery. Low vs. high levamisole exposure was
categorized according to a levamisole–cocaine ratio (LCR)
in hair samples of the participants. Both compounds were
measured by cutting-edge quantitative hair analyses. In
line with the above mentioned literature of cocaine-
induced cognitive dysfunctions and levamisole-induced
neurotoxic effects, we hypothesized that higher levamisole
exposure is associated with more severe cognitive
dysfunctions.
Based on the ﬁndings from Study 1, showing sig-
niﬁcantly worse executive functions in highLevCU com-
pared to lowLevCU, we subsequently performed a second
study with structural magnetic resonance imaging (MRI)
in a subsample with similar group classiﬁcation criteria. In
Study 2, we focused on regions-of-interest (ROI) in the
frontal lobe—which have been consistently linked to
executive function measures used in Study 118-21 as well
as on an occipital control region in order to examine
whether these levamisole-related cognitive dysfunctions
are speciﬁcally associated to structural alterations of the
frontal cortex. Accordingly, we expected that high leva-
misole exposure is linked to cortical thinning explicitly in
the frontal lobe.
Materials and Methods
Participants
Study 1
The present data were collected as part of the Zurich
Cocaine Cognition Study (ZuCo2St). The study included
75 CU, 78 healthy and stimulant-naive healthy controls
(for recruitment and selection details see Methods S1).
The three groups were matched for age, verbal intelli-
gence, sex, and smoking status. The sample of Study
1 shows a 91% overlap with a sample that was previously
published15. Exclusion criteria for all participants were an
acute or previous neurological disorder or head injury,
any clinically signiﬁcant medical disease, and use of pre-
scription drugs affecting the brain. Additional speciﬁc
exclusion criteria for both CU groups were the use of
opioids, polysubstance use, and any Axis I DSM-IV adult
psychiatric disorder—with the exception of cocaine, can-
nabis, and alcohol abuse; a history of affective disorders
(acute major depression was excluded); and attention-
deﬁcit hyperactivity disorder (ADHD). Speciﬁc exclusion
criteria for the control subjects were any current or for-
mer Axis I DSM-IV psychiatric disorder and any form of
addiction or regular illegal drug use (lifetime > 15 occa-
sions), with the exception of recreational cannabis use.
Inclusion criteria for the two user groups were cocaine as
primary used illegal drug, cocaine use of >0.5 g per month,
and an abstinence duration of <6 months. Before the
testing session, participants were asked to abstain from
illegal substances for at least 72 h and not to consume
alcohol for 24 h. Compliance with these instructions was
controlled by urine drug screenings (Methods S2). All
participants in both studies provided written informed
consent and were compensated for their participation.
Both studies were approved by the Cantonal Ethics
Committee of Zurich.
Study 2
A total of 29 CU and 38 healthy cocaine-naive controls
were included in Study 2. A subsample of 17 individuals
previously participated in Study 1 (8 controls, 9 CU; for
details see Methods S3). Exclusion and inclusion criteria
for CU and healthy controls were largely identical to
Study 1, apart from that psychiatric medication was
allowed in CU in Study 2. Moreover, six participants with
alcohol dependence (three in each CU group) and two
highLevCU with opioid co-use were included for power
reasons. However, the inclusion of these participants did
not affect the main results (Tables S1/S2). Participants
were mostly right-handed (92.5%) and there was no group
difference in handedness (χ2(2)= 3.85, p= 0.15).
Group classiﬁcation
When available, 6 cm hair samples were cut from the
occiput enabling to objectively estimate drug use and
levamisole exposure during the last 6 months. Hair
samples were analyzed with liquid chromatography-
tandem mass spectrometry (Methods S2). As in Study 1
only 2 of 75 CU (2.7%) and in Study 2 only 1 of 29 CU
(3.4%) did not display any traces of levamisole in hair, we
decided to compare low vs. high exposure groups. The
decisive criterion for the group assignment was a LCR
(levamisole concentration/cocaine concentration) higher/
lower than 25%. The LCR-cutoff of 25% was equal to the
mode value in the right-skewed LCR distribution curve
(Figure S1).
Study 1
CU were split into 26 CU with a LCR of <25% (low
levamisole exposure CU, lowLevCU) and 49 CU with a
LCR of >25% (high levamisole exposure CU, high-
LevCU). For 28 of the 75 CU, <6 cm were available so
that at least 3 cm samples were analyzed (3-month drug
exposure).
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Study 2
CU were assigned to either the lowLevCU (n= 12) or
the highLevCU (n= 17) group, respectively. For 10 out of
29 CU, only 3 cm hair samples were available.
Procedure
Trained psychologists conducted the Structured Clin-
ical Interview (SCID-I) according to DSM-IV22. Drug use
was assessed with the Interview for Psychotropic Drug
Consumption and ADHD symptoms by means of the
ADHD self-rating scale (ADHD-SR)23,24 The verbal IQ
was estimated by a standard German vocabulary test25.
Neuropsychological test battery (Study 1)
The test battery consisted of the Letter Number
Sequencing Task (LNST)26 a German version of the Rey
Auditory Verbal Learning Test (RAVLT)27 and four tests
from the Cambridge Neuropsychological Test Automated
Battery (CANTAB, http://www.cantab.com): Rapid Visual
Processing (RVP), Spatial Working Memory (SWM),
Intra/Extradimensional Set-Shifting (IED), and Paired
Associates Learning (PAL). Analogous to our previous
work15,28, 15 predeﬁned cognitive test parameters were z-
transformed on the basis of means and standard devia-
tions of the control group (n= 78) and—in respect of data
reduction—combined into four cognitive domains
(attention, working memory, declarative memory, and
executive function). These four domains were further
equally integrated into a global cognitive index (GCI)15,28.
Structural MRI acquisition and image processing (Study 2)
All subjects were scanned using a 3T Philips Achieva
whole-body scanner equipped with a 32-channel receive
head coil. High-resolution structural scans were collected
using a standard T1-weighted 3D magnetization-prepared
rapid gradient echo (MPRAGE) pulse sequence with
repetition time (TR)= 8.08 ms, echo time (TE)= 3.7, ﬁeld
of view (FOV)= 240×240mm, 160 slices, voxel size of
(1×1×1)mm3. Cortical surface reconstruction was per-
formed using the software package FreeSurfer v5.3.0
(http://surfer.nmr.mgh.harvard.edu/, Methods S4)29–31.
ROIs were extracted by parcelating the cortex using the
Desikan–Killiany Atlas32. Based on the ﬁndings from
Study 1, we restricted our analysis to ROIs in the lateral
frontal lobes. Next to the mean cortical thickness over the
whole cortical surface, our analysis included the middle
frontal gyrus (MFG, caudal and rostral MFG), inferior
frontal gyrus (IFG, pars opercularis, pars orbitalis, pars
triangularis), and the lateral orbitofrontal gyrus (lOFG).
We also included the superior frontal gyrus (SFG), a
region associated with executive functions33. The peri-
calcarine cortex (primary visual cortex) was used as a
control region due to its low concentration of dopamine
transporters34,35 and low involvement in executive
functions (Figure S2). As we did not expect lateralized
effects of a systemic drug application, extracted thickness
values for each cortical area were averaged across hemi-
spheres. This procedure was additionally justiﬁed as cor-
tical thickness in all ROIs was signiﬁcantly correlated
between the right and left hemisphere (Methods S5).
Thickness measures within the ROIs were z-transformed
on the basis of means and standard deviations of the
control group (n= 38) for better comparisons between
the ROIs.
Statistical analysis
Demographic and drug use data were analyzed with
Pearson’s χ2 tests, Students t tests, and analyses of var-
iance (ANOVA), where appropriate. Group differences
analyses in cognitive performance and cortical thickness
were conducted by analyses of covariance (ANCOVA),
followed by Sidak-corrected post hoc comparisons. In
accordance with our previous study15, age and verbal IQ
were introduced as covariates. Because ADHD has been
linked to cognitive functioning in CU15,28, and to altera-
tions in brain structure36,37, all ANCOVAs were addi-
tionally adjusted for the ADHD-SR score24. Given that
lowLevCU and highLevCU 1) paid similar average prices
for 1 g cocaine (Table 1, Table S3) and 2) reported
comparable socioeconomic background in both studies
(Table S4), socioeconomic status was not considered as a
covariate. In the ANCOVAs that focused on the cocaine
group comparison (lowLevCU vs. highLevCU), we intro-
duced two further covariates: abstinence duration (as
lowLevCU and highLevCU differed in self-reported days
since last use, see Table 1) and cumulative cocaine dose
because of the increased risk of cognitive impairment by
ascending lifetime use of cocaine15. An additional cortical
thickness analysis including duration of cocaine intake
was calculated to control for differences between the two
CU groups in Study 2 (Table S3). For correlation analyses
the drug use parameters were log-transformed because
they deviated from the normal distribution (Shapiro–Wilk
W < 0.001). All conﬁrmatory statistical comparisons were
carried out on a signiﬁcance level of p < 0.05.
Results
Study 1
Demographic characteristics and drug use
As intended by the matching procedure, the three
groups did not differ regarding age, verbal IQ, sex dis-
tribution, and smoking status (Table 1). Additionally,
there were no differences regarding the average price paid
for 1 g of cocaine (Table 1) and socioeconomic status
between both groups (Table S4). However, both CU
groups had signiﬁcantly fewer years of education and
higher BDI scores than controls but did not differ from
each other. Moreover, highLevCU displayed signiﬁcantly
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Table 1 Demographic data and drug use pattern Study 1
Controls (n= 78) LowLevCU (n= 26) HighLevCU (n= 49) Valuea df, dferr p
Age (y) 30.2 (8.9) 33.0 (9.5) 31.5 (9.1) F= 1.03 2.150 0.36
Sex (f/m) 23/55 7/19 11/38 x2= 0.76 2 0.68
Verbal IQ (MWT-B)b 105.4 (9.2) 101.4 (8.7) 102.2 (10.7) F= 2.50 2.150 0.09
Education (y) 10.7 (1.7) 9.8 (1.3)* 9.8 (1.7)** F= 6.18 2.150 0.003
Smoking (y/n)c 57/21 23/3 39/10 x2= 2.81 2 0.25
BDI scored 4.4 (4.4) 8.4 (6.1)* 9.6 (8.2)*** F= 12.25 2.150 < 0.001
ADHD-SR scoree 7.6 (4.7) 11.2 (6.3) 15.9 (9.1)***° F= 23.78 2.150 < 0.001
Cocaine
Times per weekg — 2.0 (2.2) 1.8 (1.9) T= 0.50 73 0.62
g per weekg — 3.8 (6.2) 3.3 (6.4) T= 0.34 73 0.74
Years of use — 7.7 (6.8) 8.6 (5.4) T=−0.63 73 0.53
Maximum dose (g/day) — 6.5 (6.7) 5.8 (6.2) T= 0.48 73 0.63
Cumulative dose (g) — 4130 (8272) 2658 (6689) T= 0.83 73 0.41
Last consumption (days)h — 29.4 (37.0) 13.3 (15.9) T= 2.12 73 0.04
Urine toxicology (neg/pos)i 78/0 21/5 33/16 x2= 1.52 1 0.22
Average price paid for 1 g (CHF)j 1 g (CHF)j — 97.5 (19.6) 87.5 (21.5) T= 1.95 73 0.06
Hair analysis
Cocaine pg/mg — 10,261 (20,667) 12,993 (24,031) T=−0.49 73 0.62
Benzoylecgonine pg/mg — 2853 (6901) 2550 (4365) T= 0.23 73 0.82
Norcocaine pg/mg — 292 (655) 312 (484) T=−0.15 73 0.88
Levamisole pg/mg — 967 (1745) 6931 (11,737) T=−3.48 73 0.001
Levamisole–cocaine ratio — 0.12 (0.1) 0.64 (0.3) T=−10.07 73 <0.001
Alcohol
Pure ethanol g per weekg 109.6 (121.9) 185.2 (281) 192.2 (204.5)* F= 3.61 2.150 0.03
Years of use 12.6 (9.0) 11.7 (7.9) 13.3 (7.2) F= 0.34 2.150 0.71
Nicotine
Cigarettes per dayg 8.8 (9.6) 16.7 (13.1)** 13.5 (10.3)* F= 6.68 2.150 0.002
Years of use 8.4 (8.7) 13.6 (9.6)* 12.9 (8.5)* F= 5.57 2.150 0.005
Cannabis
g per weekg 0.4 (0.9) 1.5 (4.0) 0.7 (1.7) F= 2.81 2.150 0.06
Years of use 4.3 (5.7) 7.4 (9.2) 9.6 (7.7)*** F= 8.61 2.150 <0.001
Cumulative dose (g) 665 (3182) 3289 (7433)* 1823 (2886) F= 4.18 2.150 0.02
Last consumption (days)h 41 (57);n= 34 31 (43);n= 14 25 (31);n= 34 F= 1.08 2.79 0.34
Urine toxicology (neg/pos)i 68/10 18/8 35/14 x2= 6.35 2 0.04
Amphetamine
g per weekg 0.0 (0.0) 0.0 (0.1) 0.1 (0.2)* F= 4.15 2.150 0.02
Years of use 0.0 (0.0) 1.1 (3.1) 1.5 (2.9)*** F= 8.23 2.150 <0.001
Cumulative dose (g) 0.0 (0.1) 6 (23.7) 28.4 (66.8)*** F= 8.14 2.150 <0.001
Last consumption (days)h F= 1.23 2.19 0.31
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higher ADHD-SR scores than lowLevCU. As a con-
sequence of the group classiﬁcation, the two CU groups
differed strongly in their absolute levamisole concentra-
tions and levamisole-related LCR but displayed
similar values in any other cocaine-related hair toxicology
or self-reported cocaine use parameter (with exception of
abstinence duration). Additionally, hair samples and
cumulative doses revealed a clear dominance of cocaine
compared with other illegal drugs, as intended by the
inclusion and exclusion criteria.
Neurocognitive measures
As shown before in this sample15, controls and
CU (lowLevCU+ highLevCU) differed signiﬁcantly
in the GCI and all four domains (F(1148)= 10.64–28.34,
p ≤ 0.001) (Table S5). Three-group ANCOVAs (controls
vs. lowLevCU vs. highLevCU) for the GCI (F(2147)= 15.26,
p < 0.001) and across all four cognitive domains (F(2147)=
6.70–10.45, p= 0.002–0.0001) showed signiﬁcant group
effects (Fig. 2a, Table S6). Linear trends across groups were
shown for all comparisons (p < 0.01–0.001), suggesting not
only a cocaine but also a levamisole effect on cognitive
functioning. The post hoc pairwise comparisons showed
that lowLevCU differed from controls in the GCI, attention,
and working memory domain, while highLevCU differed
from controls in all cognitive domains (Fig. 2a). In general,
effect sizes were considerably higher for highLevCU (d=
0.57–0.80) compared to lowLevCU (d= 0.32–0.59). Sub-
sequently, to adjust for even subtle differences in cocaine
use intensity, both CU groups were compared using
ANCOVAs in which abstinence duration und cumulative
lifetime dose of cocaine were additionally included. Here,
highLevCU showed a stronger impairment of executive
functions with a medium effect size compared to lowLevCU
(F(1,68)= 5.02, p < 0.05, d= 0.55). Additionally, the GCI (F
(1,68)= 3.21, p= 0.08, 0.42) and declarative memory (F
(1,68)= 3.21, p= 0.08, d= 0.44) showed statistical trends
towards signiﬁcance with approximately medium effect
sizes (Fig. 2b). The impact on executive function was mainly
driven by a worse performance in the IDE task and
recall consistency (Table S7), indicating more pronounced
impairments speciﬁcally in rule acquisition and
reversal learning as well as in memory organization in
highLevCU. An exploratory analysis of the IDE stages
revealed that highLevCU made more errors speciﬁcally in
the intradimensional set-shifting (pre-ED errors: (F(1,68)=
0.01, p < 0.05, d= 0.64) but not in the extradimensional set-
shifting (ED errors: F(1,68)= 6.02, p= 0.94, d= 0.02;
Figure S3). Notably, in a combined CU group,
the executive function performance correlated negatively
with the log-transformed levamisole values in hair samples
(r=−0.23, p < 0.05, one-tailed; Figure S4).
Table 1 continued
Controls (n= 78) LowLevCU (n= 26) HighLevCU (n= 49) Valuea df, dferr p
122 (0)
n= 1
97 (71)
n= 5
59 (54)
n= 16
Hair analysis pg/mg 1 (7) 24 (69) 118 (313)** F= 6.57 2.150 0.002
MDMA
Tablets per weekg 0.0 (0.0) 0.0 (0.0) 0.1 (0.2)***° F= 7.93 2.150 <0.001
Years of use 0.3 (1.7) 1.3 (2.4) 3 (4.5)*** F= 11.83 2.150 <0.001
Cumulative dose (tablets) 0.9 (3.2) 69.9 (154.3)* 54.1 (168.4)* F= 5.21 2.150 0.007
Last consumption (days)h 5 (0)
n= 1
92 (0)
n= 1
71 (87)
n= 17
F= 0.31 2.16 0.741
Hair analysis pg/mg 4 (23) 177 (337) 831 (1902)***° F= 8.95 2.150 <0.001
Hallucinogens
Cumulative dose (times) 0.7 (1.8) 9.7 (22.2)** 6.8 (10.5)** F= 8.76 2.150 <0.001
Means and standard deviations. Signiﬁcant p values are shown in bold
aANOVA (all groups; signiﬁcant Sidak post hoc test vs. control group: *p < 0.05; **p < 0.01; ***p < 0.001; vs. lowLevCU: °p < 0.05; °°p < 0.01); x² test (all groups/cocaine
users only) for frequency data; Independent t-test (cocaine users only)
bVerbal IQ was assessed by the Mehrfachwahl–Wortschatz–Intelligenztest25
cSmoking habits were assessed by the Fagerstroem Test of Nicotine Dependence63
dBDI Beck Depression Inventory64
eADHD-SR ADHD self-rating scale24
fCraving for cocaine was assessed by the Brief-CCQ65
gAverage use during the last 6 months
hLast consumption is averaged only for persons who used the drug in the last 6 months. In this case, sample size (n) is shown
iCut-off values for cocaine= 150 ng/ml and for Tetrahydrocannabinol 50 ng/ml66
jPrice for 1 g cocaine in Swiss Francs paid by cocaine users (self-report). The quoted price is presumably below the real street price as some users paid reduced rates at
intermediaries. Moreover, individuals who got the cocaine for free (e.g., as a gift) were excluded (n= 1 lowLevCU and n= 1 highLevCU)
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Study 2
Demographic characteristics and levamisole analysis
Again, the three groups did not differ regarding edu-
cation, sex distribution, smoking status, average price paid
for 1 g of cocaine (Table S3), and socioeconomic status
(Table S4). As in Study 1, the two CU groups showed
higher BDI and ADHD-SR scores than healthy controls.
Moreover, the lowLevCU had a signiﬁcant lower verbal
IQ than the highLevCU group and the controls. Hair
toxicology measures between the two CU groups did only
differ for the measured levamisole concentration as well
as the levamisole-related LCR.
Fig. 2 Mean z-scores and standard errors for the global cognitive index (GCI) and the four cognitive domains. a All values corrected for age,
verbal IQ, and ADHD (based on all three groups). Sidak post hoc tests: *p < 0.05; **p < 0.01; ***p < 0.001. Cohen’s d vs. controls. b Cocaine user group
values corrected for age, verbal IQ, ADHD, abstinence duration, and cumulative cocaine dose (based on cocaine user groups). Sidak post hoc tests: *p
< 0.05. Cohen’s d lowLevCU vs. highLevCU
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Thickness measures
Three-group comparisons revealed signiﬁcant group
effects on cortical thickness for the whole brain ROI (F
(2,61)= 3.90, p < 0.05), and the MFG (F(2,61)= 3.61, p <
0.05; Fig. 3a, Table S1). Both measures showed signiﬁcant
linear trends across groups (p < 0.05) and post hoc pair-
wise comparisons indicated that cortical thickness was
signiﬁcantly decreased in highLevCU compared to con-
trols. As in Study 1 two additional cocaine-related cov-
ariates were added for the two-group ANCOVAs
Fig. 3 Mean cortical thickness (in mm) and standard errors for the whole brain and ﬁve regions of interest. a All values corrected for age,
verbal IQ, and ADHD (based on all three groups). Sidak post hoc tests: *p < 0.05. Cohen’s d vs. controls. b Cocaine user group values corrected for age,
verbal IQ, ADHD, abstinence duration, and cumulative cocaine dose (based on cocaine user groups). Sidak post hoc tests: *p < 0.05. Cohen’s d
lowLevCU vs. highLevCU
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(lowLevCU vs. highLevCU): abstinence duration and
cumulative lifetime dose (Fig. 3b, Table S2). A signiﬁcant
group difference was found for the MFG showing a strong
effect size (F(1,22)= 5.65, p < 0.05, d= 0.84).
This effect remained signiﬁcant, when alcohol (pure
ethanol in g per week) was considered as an additional
covariate (F(1,21)= 5.16, p < 0.05, d= 0.80) of potential
impact on cortical thickness. ANCOVAs for whole brain,
IFG, and lOFG—albeit not statistically signiﬁcant—
showed medium effect sizes (F(1,22)= 1.52–2.74, p=
0.23–0.11, d= 0.45–0.56). A small effect was applicable
for the SFG (F(1,22)= 0.18, p= 0.67, d= 0.17). By con-
trast, no effect was found for the pericalcarine gyrus as
expected (F(1,22)= 0.00, p= 0.99, d= 0.00). Importantly,
MFG thickness was negatively correlated with the log-
transformed levamisole hair concentration (r=−0.32, p
< 0.05, one-tailed; Figure S5).
Discussion
The aim of the present studies was to examine whether
the worldwide highly prevalent cocaine adulterant leva-
misole is associated with higher risks for cognitive
impairment and structural brain alterations in chronic CU
with recent levamisole exposure. We ﬁrst demonstrated
that highLevCU showed signiﬁcantly worse executive
functions (Cohen’s d= 0.55) compared to individuals
with equivalent cocaine use intensity but lower levamisole
hair concentrations. Although not signiﬁcant, similar
patterns with approximately medium effect sizes were also
found for the global cognition score (d= 0.42) and
declarative memory performance (d= 0.44), but not for
attention (d= 0.12) and working memory (d= 0.04).
Notably, compared to stimulant-naive healthy controls,
signiﬁcant cognitive deﬁcits were still present in CU with
low levamisole exposure. Based on these initial ﬁndings,
we subsequently performed a second study employing
structural MRI analyses. In line with the results from the
cognitive study, we found signiﬁcantly reduced cortical
thickness in the MFG of CU with high levamisole hair
concentrations (d= 0.84). Moreover, even though not
statistically signiﬁcant-related effects were shown for the
whole brain (d= 0.56), IFG (d= 0.45), and lOFG (d=
0.54), while in an occipital control region no levamisole
effect was observable (d= 0.00).
In sum, these ﬁndings conﬁrm our previous proposi-
tion15,16 that cocaine use is linked with broad cognitive
impairments in the present sample. However, also the
adulterant levamisole seems to be related to these
impairments, most strongly in the executive functions but
also in declarative memory and global cognitive functions.
Moreover, levamisole-associated reductions of cortical
thickness were also found in lateral frontal brain areas,
indicating possible neuroanatomical underpinnings of
executive function deﬁcits found in highLevCU. In line
with an early animal study12, these results suggest that
levamisole is linked to neurotoxic effects also in humans
with regular use of levamisole-contaminated cocaine.
Importantly, because highLevCU and lowLevCU did not
differ in their socioeconomic background and paid com-
parable prices for their street cocaine, low income is likely
not an alternative explanation for the cognitive and cor-
tical alterations found in cocaine users with high leva-
misole exposure.
Previous studies consistently showed strong deﬁcits of
CU in attention and working memory, whereas the het-
erogeneous concept of executive functions was usually
less affected15,38–40. Here, we also found clear cocaine but
no pronounced levamisole effects in the domains of
attention and working memory but a signiﬁcant levami-
sole effect on executive functions. Thus, one might
speculate that at least some of the reported discrepant
ﬁndings in the newer literature regarding executive
function impairments41 might be explained by differences
in recent levamisole exposure. As levamisole was pro-
posed to be metabolized into the amphetamine-like sti-
mulant aminorex and other metabolites1,6,7, and previous
reports showed pronounced executive function decre-
ments in chronic amphetamine users42,43, the present
effect might not be linked to levamisole alone but also to
its metabolic products.
The indicated levamisole effect on the executive func-
tion domain was mainly driven by low performance in an
attentional set-shifting/reversal learning task (IED) and
worse recall consistency in a verbal learning task
(RAVLT), while the strategy score of a spatial working
memory task (SWM) was less affected. This supports the
assumption that levamisole might have little effect on
working memory processes per se but impacts cognitive
ﬂexibility and memory organization. Remarkably, these
speciﬁc cognitive impairments are well in line with the
found structural alterations in the MFG, given that (1) the
MFG is prominently involved in attentional set-shifting
and reversal learning44,45 and (2) patients with focal
frontal lesions have difﬁculties in memory organization
such as recall consistency18,19. Moreover, frontal lobe
atrophy has been shown as the most consistent predictors
for recall consistency in patients with multiple sclerosis46.
Finally, age-related changes presumably of the prefrontal
cortex (including predominantly the MFG)47,48 as well as
excitotoxic prefrontal lesions49 are associated with
impairments in set-shifting in monkey models.
To date, the exact neurobiological substrates behind the
cocaine-related cognitive alterations are still not fully
understood50. Cocaine is an unspeciﬁc monoamine
reuptake inhibitor with high afﬁnity for dopamine, ser-
otonin, and norepinephrine transporters (DAT, SERT,
and NET)51. Thus, cognitive deﬁcits most likely depend
on adaptions involving regions with high concentrations
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of monoamine responsive cells such as the prefrontal
cortex52. Also the exact neurobiological effects of leva-
misole remain unclear. Recent research suggested that
levamisole has only minor effects on monoamine trans-
porter6. Yet, the metabolite aminorex, has a similar afﬁ-
nity to NET and DAT as cocaine, while showing less
binding to the SERT6. However, it is not fully clear if
aminorex is able to augment cocaine effects in humans in
general, but due to its longer half-life it might at least
prolong the stimulant effects of cocaine6,53. Interestingly,
speciﬁc impairments in attentional set-shifting were
reported for noradrenergic but not cholinergic deaf-
ferentation of the medial prefrontal cortex—the homolog
of the primate dorsolateral prefrontal cortex in rats54.
Given that we previously proposed that CU might show
neuroplastic adaptations in the noradrenaline system55,56
one could speculate that not only cocaine but speciﬁcally
a cocaine–aminorex combination can disrupt the nora-
drenaline transmission. Moreover, medically prescribed
levamisole intake is supposed to cause multifocal
inﬂammatory leukoencephalopathy57,58, a disease asso-
ciated with white matter lesions. Thus, executive function
impairments might be mainly explained by levamisole (or
its metabolites) as white matter lesions are associated with
cognitive dysfunctions in general59 and executive function
deﬁcits in particular60. Importantly, executive function
deﬁcits are also strongly linked to gray matter alterations
in the prefrontal cortex61. Thus, executive function deﬁ-
cits in highLevCU are likely explained by neuroanatomical
alterations of the prefrontal cortex beyond the cortical
abnormalities linked to cocaine consumption per se42.
A limitation of this study is that the objective hair tox-
icology parameters covered only the last 3 to 6 months.
Consequently, the group classiﬁcation based on the LCR
reﬂected a recent but not necessarily a long-term levamisole
exposure. Moreover, we did not apply a neuropsychological
test battery in Study 2 at the time of structural imaging and,
thus, were not able to directly correlate cognitive perfor-
mance with cortical thickness scores. Finally, the applied
cross-sectional case–control study design makes it impos-
sible to determine the causal relationship between levami-
sole and neurocognitive and imaging measures.
In conclusion, CU with high levamisole exposure
showed signiﬁcantly worse executive functioning than CU
with comparable cocaine use severity but low levamisole
contamination. Moreover, high levamisole exposure was
associated with lower cortical thickness, primarily for the
MFG but also—even though not statistically signiﬁcant—
in additional frontal regions and on a whole brain level.
Altogether, our results indicate that exposure to high
doses of levamisole during the last months (covered by
the hair analyses) goes along with pronounced neuro-
cognitive and cortical alterations in CU, strongly indi-
cating a possible neurotoxic effect of levamisole in
humans. Consequently, CU should be better informed
about the consequences of levamisole-adulterated cocaine
and drug policy makers should consider prevention and
harm reduction programs, which lead to a reduction of
levamisole contamination of street cocaine such as drug-
checking services for users62.
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Methods S1. Recruitment and selection Study 1. 
The recruitment focused on the greater area of Zurich and lasted from January 2010 until October 2012. 
Participants were recruited via advertisements in local newspapers, online media, drug prevention and 
treatment centers, psychiatric hospitals, and by word of mouth. After initial standardized telephone 
interviews, 250 subjects (108 psychostimulant-naïve controls, 142 CU) were considered to be eligible for 
inclusion in the cross-sectional sample. All subjects were aged between 18 and 60 years and had sufficient 
German language skills. Seventy-one participants were excluded because hair analyses revealed illegal drug 
use not declared in the interviews (e.g., opioids, excessive MDMA use) or due to a lack of cocaine use. 
Twelve controls were excluded due to matching reasons (age, verbal IQ, and smoking) between groups.  
Furthermore, the data of four participants could not be analyzed because of technical problems during the 
test session and ten participants provided no or not enough hair to be toxicologically analyzed. This lead to a 
final sample of 75 CU and 78 healthy controls. 
 
 
Methods S2. Urine and hair toxicology analyses. 
Urine toxicology analyses comprised the compounds/substances: tetrahydrocannabinol, cocaine, 
amphetamines, benzodiazepines, opioids, and methadone and were assessed by a semi-quantitative enzyme 
multiplied immunoassay method using a Dimension RXL Max (Siemens, Erlangen, Germany). 
To characterize drug use and levamisole exposure over the last months objectively, hair samples were 
collected and analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS). If participants’ 
hair was long enough, one sample of six cm hair (from the scalp) was taken from the occiput and 
subsequently divided into two subsamples of three cm length. The following compounds were assessed: 
levamisole, cocaine, benzoylecgonine, ethylcocaine, norcocaine, amphetamine, methamphetamine, MDMA, 
MDEA, MDA, ephedrine, morphine, codeine, dihydrocodeine, methadone EDDP (primary methadone 
metabolite), oxycodone, tramadol, and methylphenidate. 
For our routine protocol a three step washing procedure with water (2min shaking, 15ml), acetone (2min, 
10ml) and finally hexane (2min, 10ml) of hair was performed. Then the hair samples were dried at ambient 
temperatures, cut into small snippets and extracted in two steps, first with methanol (5ml, 16h, 
ultrasonication) and a second step with 3ml MeOH acidified with 50µl hydrochloric acid 33% (3h, 
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ultrasonication). The extracts were dried and the residue reconstituted with 50µl MeOH and 500µl 0.2mM 
ammonium formate (analytical grade) in water. As internal standards deuterated standards of the following 
compounds were used, added as mixture of the following compounds: cocaine-d3, benzoylecgonine-d3, 
ethylcocaine-d3, morphine-d3, MAM-d3, codeine-d3, dihydrocodeine-d3, amphetamine-d6, 
methamphetamine-d9, MDMA-d5. MDEA-d6, MDA-d5, methadone-d9, EDDP-d3, methylphenidate-d9, 
tramadol-d3, oxycodone-d3, and ephedrine-d3. All deuterated standards were from ReseaChem (Burgdorf, 
Switzerland), the solvents for washing and extraction were of analysis grade and obtained from Merck 
(Darmstadt, Germany); LC-solvents were of HPLC grade and were obtained from Sigma Aldrich (Buchs, 
Switzerland). 
The LC-MS/MS apparatus was an ABSciex QTrap 3200 (Analyst software Version 1.5, Turbo V ion source 
operated in the ESI mode, gas 1, nitrogen (50psi); gas 2, nitrogen (60psi); ion spray voltage, 3500V; ion 
source temperature, 450°C; curtain gas, nitrogen (20psi) collision gas, medium), with a Shimadzu 
Prominence LC-system (Shimadzu CBM 20 A controller, two Shimadzu LC 20 AD pumps including a 
degasser, a Shimadzu SIL 20 AC autosampler and a Shimadzu CTO 20 AC column oven, Shimadzu, 
Duisburg, Germany). Gradient elution was performed on a separation column (Synergi 4µ POLAR-RP 80A, 
150x2.0 with a POLAR-RP 4x2.0 Security Guard Cartridge, (Phenomenex, Aschaffenburg, Germany). The 
mobile phase consisted of 1mM ammonium formate buffer adjusted to pH 3,5 with formic acid (eluent A) 
and acetonitrile containing 1mM ammonium formate and 1mM formic acid (eluent B). The analysis was 
performed in MRM mode with two transitions per analyte and one transition for each deuterated internal 
standard, respectively. 
The above mentioned substances were measured in a first analytical step. In a second step, we analyzed 
levamisole by the same method. This additional levamisole measurement (definition of MRM measurement 
parameters and retention time) based on the internal standard of cocaine-d3 (calibration between reference 
measurement an 25‘000 pg/mg, 4 calibrators, linear, r2=.99).  
 
 
Methods S3. Recruitment and selection Study 2. 
A subsample 17 individuals of Study 1 also participated in Study 2. The remaining 61 participants were re-
invited from an additional cross-sectional study, which was conducted in the Zurich area between November 
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2015 and November 2016. As in Study 1, all participants were aged between 18 and 60 and had sufficient 
German language skills. Six participants had to be excluded despite reporting stable consume over 0.5g per 
month their hair concentration of cocaine did not reach the detectable level of 500 pg/mg. One CU provided 
no hair sample and one participant had to be excluded as the hair analysis revealed a clear polydrug use 
pattern. Unexpectedly, one control subject had to be excluded due to a positive urine sample for opioids, one 
due to cocaine traces in hair, and one due to regular intake of strong migraine medication. Leading to a final 
sample of 29 CU and 38 healthy controls. 
 
 
Methods S4. FreeSurfer details. 
In summary, the processing pipeline included the following steps: motion correction, automated Talairach 
transformation, non-parametric non-uniform intensity normalization (N3), removal of non-brain tissue (skull 
stripping), and generation of individual cortical surface models. Once the surfaces were reconstructed, 
several anatomical parameters were extracted at each vertex of the tessellated surface. Cortical thickness was 
defined as the minimal distance between the white/gray matter boundary and the pial surface1 and was 
formerly validated by using manual segmentations2.  
 
 
Methods S5. ROI-correlations between the right and the left hemisphere. 
Mean thickness: r=.97, p<.001; superior frontal gyrus: r=.84, p<.001; middle frontal gyrus: r=.76, p<.001; 
inferior frontal gyrus: r=.75, p<.001; lateral orbitofrontal gyrus: r=.55, p<.001; pericalcarine gyrus: r=.62, 
p<.001.  
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Table S1. Cortical thickness measures Study 2. Three-group-comparison.  
Cohen's d 
 Mean cortical thickness measures  Controls LowLevCU HighLevCU F df, dferr p 
Controls  
vs. 
LowLevCU 
Controls  
vs. 
HighLevCU 
LowLevCU 
vs. 
HighLevCU 
All participants included  n=38 n=12 n=17       
          
Whole brain  2.51 (0.02) 2.48 (0.03) 2.43 (0.02)* 3.90 2,61 .03 .31 .75 .44 
Superior frontal  2.84 (0.02) 2.79 (0.04) 2.76 (0.03) 1.603 2,61 .21 .27 .51 .24 
Middle frontal 2.49 (0.02) 2.47 (0.03) 2.40 (0.03)* 3.605 2,61 .03 .13 .72 .60 
Inferior frontal 2.64 (0.02) 2.64 (0.04) 2.59 (0.03) 0.669 2,61 .52 .01 .29 .30 
Lateral orbitofrontal 2.64 (0.02) 2.59 (0.04) 2.56 (0.03) 1.958 2,61 .15 .37 .61 .24 
Pericalcarine  1.57 (0.02) 1.53 (0.03) 1.52 (0.03) 1.045 2,61 .36 .36 .48 .12 
          
Without alcohol dependent participants n=38 n=9 n=14       
          
Whole brain  2.51 (0.01) 2.47 (0.03) 2.44 (0.02)* 3.214 2,55 .05 .39 .72 .33 
Superior frontal 2.84 (0.02) 2.79 (0.04) 2.77 (0.04) 1.251 2,55 .29 .34 .44 .09 
Middle frontal 2.49 (0.02) 2.47 (0.03) 2.41 (0.03) 2.928 2,55 .06 .14 .70 .56 
Inferior frontal 2.64 (0.02) 2.63 (0.05) 2.60 (0.04) 0.372 2,55 .69 .06 .26 .20 
Lateral orbitofrontal 2.64 (0.02) 2.59 (0.04) 2.58 (0.03) 1.351 2,55 .28 .40 .50  .10 
Pericalcarine 1.57 (0.02) 1.49 (0.04) 1.53 (0.03) 1.954 2,55 .15 .80 .40 .40 
          
Without opioid using participants n=38 n=12 n=15       
          
Whole brain  2.51 (0.02) 2.47 (0.03) 2.42 (0.03)* 4.384 2,59 .02 .34 .83 .49 
Superior frontal 2.84 (0.02) 2.79 (0.04) 2.75 (0.04) 1.738 2,59 .19 .29 .55 .26 
Middle frontal 2.49 (0.02) 2.47 (0.03) 2.40 (0.03)* 3.929 2,59 .03 .17 .80 .63 
Inferior frontal 2.64 (0.02) 2.64 (0.04) 2.58 (0.04) 0.95 2,59 .39 .01 .36 .37 
Lateral orbitofrontal 2.64 (0.02) 2.59 (0.04) 2.56 (0.04) 1.7 2.59 .19 .34 .60 .26 
Pericalcarine 1.56 (0.02) 1.53 (0.03) 1.52 (0.03) 0.747 2,59 .48 .32 .42 .10 
  
 
Estimated means (in mm) and standard errors. ANCOVA (all groups, corrected for age, verbal IQ, and ADHS-SR sum score). Significant p values are shown in bold. Significant Sidak post-hoc test vs. 
control group: *p<.05; **p<.01; ***p<.001.  
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Table S2. Cortical thickness measures Study 2. Cocaine user group comparison. 
  LowLevCU HighLevCU F df, dferr p Cohen's d 
All participants included  n=12 n=17         
Whole brain  2.47 (0.03) 2.41 (0.02) 2.74 1,22 .11 .56 
Superior frontal 2.76 (0.05) 2.74 (0.04) 0.18 1,22 .67 .17 
Middle frontal 2.47 (0.03) 2.38 (0.02) 5.65 1,22 .03 .84 
Inferior frontal 2.62 (0.04) 2.55 (0.03) 1.52 1,22 .23 .45 
Lateral orbitofrontal 2.60 (0.04) 2.52 (0.04) 1.55 1,22 .23 .54 
Pericalcarine 1.51 (0.03) 1.51 (0.03) 0.00 1,22 .99 .00 
       
Duration included as additional covariate n=12 n=17     
       
Whole brain  2.47 (0.03) 2.40 (0.02) 3.22 1,21 .09 .59 
Superior frontal 2.77 (0.04) 2.73 (0.03) 0.35 1,21 .56 .22 
Middle frontal 2.47 (0.03) 2.37 (0.02) 5.67 1,21 .03 .86 
Inferior frontal 2.63 (0.04) 2.54 (0.03) 2.14 1,21 .16 .50 
Lateral orbitofrontal 2.60 (0.04) 2.52 (0.03) 2.51 1,21 .13 .62 
Pericalcarine 1.51 (0.04) 1.51 (0.03) 0.00 1,21 .99 .00 
       
Without alcohol dependent participants n=9 n=14 
Whole brain  2.47 (0.03) 2.41 (0.02) 2.16 1,16 .16 .55 
Superior frontal 2.77 (0.05) 2.75 (0.04) 0.07 1,16 .80 .12 
Middle frontal 2.46 (0.03) 2.38 (0.02)  4.80 1,16 .04 .84 
Inferior frontal 2.62 (0.05 2.56 (0.03) 1.14 1,16 .30 .45 
Lateral orbitofrontal 2.61 (0.05) 2.53 (0.04) 1.31 1,16 .27 .58 
Pericalcarine 1.48 (0.04) 1.53 (0.03) 0.85 1,16 .37 .53 
       
Without opioid using participants n=12 n=15 
       
Whole brain  2.47 (0.03) 2.4 (0.02) 3.20 1,20 .09 .58 
Superior frontal 2.76 (0.05) 2.73 (0.04) 0.21 1,20 .65 .18 
Middle frontal 2.46 (0.03) 2.37 (0.02) 6.13 1,20 .02 .83 
Inferior frontal 2.62 (0.04) 2.53 (0.03) 2.61 1,20 .12 .56 
Lateral orbitofrontal 2.61 (0.04) 2.51 (0.04) 2.37 1,20 .14 .66 
Pericalcarine 1.51 (0.04) 1.52 (0.03) 0.00 1,20 .96 .03 
  
 
Estimated means (in mm) and standard errors. ANCOVA (only cocaine user groups, corrected for age, verbal IQ, ADHS-SR sum 
score, abstinence duration, and cumulative lifetime dose of cocaine). Significant p values are shown in bold. 
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Table S3. Demographic data and drug use pattern of Study 2.  
 
Controls  
(n=38) 
LowLevCU 
(n=12) 
HighLevCU 
(n=17) Value
a df, dferr p 
Age (y) 31.4 (7.6) 31.2 (4.7) 36.6 (7.9) F=3.29 2,64 .04 
Sex (f/m) 16/22 3/9 3/14 x2=3.59 2 .17 
Verbal IQ (MWT-B)b,i 109.0 (12.0) 96.4 (7.0) **° 107.6 (10.2) F=6.31 2,64 .003 
Education (y) 10.5 (1.5) 10.3 (1.6) 10.3 (1.5) F=0.516 2,64 .60 
Smoking (y/n)c 29/9 11/1 13/4 x2=1.40 2 .50 
BDI scored 2.3 (4.7) 9.2 (7.0)** 8.4 (7.8)** F=9.340 2,64 <.001 
ADHD-SR scoree,i 6.3 (5.6) 15.6 (10.2)** 16.0 (8.4)*** F=14.00 2,64 <.001 
Cocaine 
Times per weekf - 1.6 (2.0) 1.2 (0.9) T=0.77 27 .45 
g per weekf - 1.9 (2.6) 1.5 (1.4) T=0.62 27 .54 
Years of use - 7.8 (4.8) 12.7 (6.6) T=-2.21 27 .04 
Maximum dose (g/day) - 2.1 (1.3) 2.5 (1.4) T=-0.85 23 .40 
Cumulative dose (g) - 1063 (1199) 1744 (1600) T=-1.25 27 .22 
Last consumption (days)g - 7.2 (7.7) 10.5 (8.2) T=-1.07 27 .29 
Urine toxicology (neg/pos)h 38/0 6/6 8/9 x2=0.02 1 .88 
Average price paid for 1g (CHF)j - 96.8 (22.4) 93.2 (13.3) T=0.53 26 .60 
Hair analysis 
   Cocaine pg/mg - 26236 (24761) 20974 (25661) T=0.55 27 .59 
   Benzoylecgonine pg/mg - 10082 (12005) 6395 (6641) T=1.06 27 .57 
   Norcocaine pg/mg - 741 (801) 546 (554) T=0.78 27 .45 
   Levamisole pg/mg - 1867 (2633) 9715 (12380) T=-2.23  27 .02 
   Levamisole-Cocaine-Ratio - 0.07 (0.1) 0.52 (0.3) T=-7.96   27 <.001 
Alcohol  
g per weekf 62.0 (68.6) 149.8 (116.6) 205.1 (178.8)*** F=9.93 2,64 <.001 
Years of use 11.8 (6.5) 9.8 (5.5) 17.1 (9.2)°* F=4.42 2,61 .02 
Nicotine  
Cigarettes per dayf 4.6 (6.1) 10.8 (8.1)* 7.9 (10.1) F=3.42 2,64 .04 
Years of use 7.8 (7.0) 10.8 (6.5) 13.7 (10.8)* F=3.24 2,64 .05 
Cannabis  
g per weekf 0.0 (0.1) 1.5 (2.2) 2.2 (6.3) F=2.75 2,64 .07 
Years of use 3.3 (5.3) 12.1 (7.5)** 9.5 (9.7)*** F=9.32 2,64 <.001 
Cumulative dose (g) 35.8 (82.9) 1925 (3329) 3353 (4419)***  F=10.02 2,63    <.001 
Last consumption (days)g 76 (59);n=11 21 (37)*;n=10 11 (11)**;n=11 F=7.96 2,29 .002 
Urine toxicology (neg/pos)h 38/0 8/4 13/4 x2=12.55 2 .002 
Amphetamine  
g per weekf 0.0 (0.0) 0.1 (0.1)** 0.0 (0.0) F=5.20 2,64 .008 
Years of use 0.1 (0.5) 2.0 (2.3)* 2.3 (3.8)** F=7.41 2,63 .001 
Cumulative dose (g) 0.2 (0.9) 190.0 (336.4)***°° 18.5 (39.9) F=8.52 2,64 .001 
Last consumption (days)g 30 (0);n=1 42 (45);n=5 60 (57);n=5 F=0.23 2,19 .80 
Hair analysis pg/mg 0 (0) 138 (198) 160 (425) F=3.64 2,64 .03 
MDMA 
Tablets per weekf 0.0 (0.0) 0.3 (0.6)* 0.2 (0.6) F=4.08 2,63 .02 
Years of use 0.2 (1.1) 3.2 (3.2) 5.4 (6.5)*** F=12.44 2,62 <.001 
Cumulative dose (tablets) 0.8 (5.1) 469.0 (1119.6)* 247.9 (469.0) F=4.24 2,62 .02 
Last consumption (days)g 91 (0);n=1 63 (57);n=9 26 (27);n=9 F=2.10 2,16 .16 
Hair analysis pg/mg 2 (9) 224 (267) 2867 (8521) F=2.77 2,64 .07 
Hallucinogens  
Cumulative dose (times) 0.6 (1.6) 2.0 (2.7) 10.9 (23.3)* F=4.50 2,61 .02 
 
Means and standard deviations. Significant p values are shown in bold.  
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a ANOVA (all groups; significant Sidak post-hoc test vs. control group: *p<.05; **p<.01; ***p<.001; vs. lowLevCU: °p<.05; 
°°p<.01); x² test (all groups/cocaine users only) for frequency data; Independent t-test (cocaine users only).  
b Verbal IQ was assessed by the Mehrfachwahl Wortschatz Intelligenztest3.  
c Smoking habits were assessed by the Fagerstroem Test of Nicotine Dependence4. 
d BDI, Beck Depression Inventory5. 
e ADHD-SR, ADHD self rating scale6. 
f Average use during the last 6 months.  
g Last consumption is averaged only for persons who used the drug in the last 6 months. In this case, sample size (n) is shown. 
h Cut-off values for cocaine = 150 ng/ml and for Tetrahydrocannabinol 50 ng/ml 7. 
i For one LowLevCU and one highLevCU, the verbal IQ and ADHS-SR score were not available due to technical problems. For 
those participants, missing values were replaced with their group mean.  
j Price for 1 g cocaine in Swiss Francs paid by cocaine users (self-report). The quoted price is presumably below the real street price 
as some users paid reduced rates at intermediaries. Moreover, individuals who got the cocaine for free (e.g., as a gift) were excluded  
(n=1 lowLevCU). 
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Table S4. Socioeconomic status (number of subjects and percent). 
 
Study 1 Study 2  
 
  
LowLevCU 
(n=26) 
HighLevCU 
(n=49)  
LowLevCU 
(n=12) 
HighLevCU 
(n=17)  
 
0 - 15'000 CHF 9 (34.6%) 12 (24.5%) 0 (0.0%) 3 (17.6%)  
15'000 - 30'000 CHF 8 (30.8%) 8 (16.3%) 1 (8.3%) 1 (5.9%)  
30'000 - 60'000 CHF 6 (23.1%) 15 (30.6%) 8 (66.7%) 7 (41.2%)  
60'000 - 90'000 CHF 2 (7.7%) 9 (18.4%) 3 (25.0%) 1 (5.9%)  
90'000 - 120'000 CHF 0 (0.0%) 4 (8.2%) 0 (0.0%) 3 (17.6%)  
120'000 CHF and more 1 (3.8%) 1 (2.0%) 0 (0.0%) 2 (11.8%)  
   
Fisher-Freeman-Halton Exact Test F=6.03, p=.28 F=7.41, p=.13  
 
 
Participants were asked how much money they had available over the past year. 
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Table S5. Neuropsychological test scores of controls vs. cocaine users in Study 1.  
 
  Controls (n=78) 
Cocaine users 
(n=75) F df, dferr p Cohen's d 
 
Global Cognitive Index  -0.07 (0.06) -0.58 (0.06) 28.34 1,148 <.001 .74 
 
Neurocognitive domain scores  
Attention -0.04 (0.10) -0.58 (0.10) 13.58 1,148 <.001 .61 
Working memory -0.11 (0.08) -0.53 (0.08) 13.32 1,148 <.001 .54 
Declarative memory -0.08 (0.10) -0.72 (0.10) 18.26 1,148 <.001 .63 
Executive functions -0.04 (0.09) -0.51 (0.10) 10.64 1,148 .001 .54 
   
 
Estimated means and standard errors. ANCOVA (all groups, corrected for age, verbal IQ, and ADHS-SR sum score). Significant p 
values are shown in bold. Significant Sidak post-hoc test vs. control group: *p<.05; **p<.01; ***p<.001. GCI and cognitive domain 
scores are z-transformed values. 
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Table S6. Neuropsychological test scores of controls vs. low LCR cocaine users vs. high LCR cocaine users in Study 1.  
Cohen's d 
  Controls (n=78) 
LowLevCU 
(n=26) 
HighLevCU 
(n=49) F df, dferr p 
Controls  
vs. 
LowLevCU 
Controls  
vs. 
HighLevCU 
LowLevCU 
vs. 
HighLevCU 
Global Cognitive Index  -0.07 (0.06) -0.47 (0.10)** -0.65 (0.08)*** 15.26 2,147 <.001 .58 .85 .27 
Neurocognitive domain scores 
Attention -0.04 (0.10) -0.56 (0.16)* -0.59 (0.12)** 6.76 2,147 .002 .59 .63 .04 
Working memory -0.11 (0.08) -0.49 (0.12)* -0.55 (0.10)** 6.70 2,147 .002 .49 .57 .08 
Declarative memory -0.08 (0.10) -0.53 (0.16) -0.84 (0.12)*** 10.45 2,147 <.001 .45 .76 .31 
Executive functions -0.04 (0.09) -0.31 (0.15) -0.64 (0.12)*** 6.81 2,147 .001 .32 .70 .38 
Neuropsychological test scores 
Attention 
RVP Discrimination performance A' 0.916 (0.01) 0.887 (0.01)* 0.893 (0.01)* 5.04 2,147 .008 .62 .49 .13 
RVP Total hits 18.21 (0.54) 15.39 (0.89)* 16.07 (0.70) 4.47 2,147 .01 .60 .45 .14 
RAVLT Supraspan trial 1 9.00 (0.24) 8.56 (0.39) 7.53 (0.31)** 6.22 2,147 .003 .19 .63 .44 
Working memory 
LNST Score 15.28 (0.33) 14.01 (0.55) 14.28 (0.43) 2.48 2,147 .09 .41 .32 .09 
SWM Total errors 20.10 (1.97) 26.66 (3.23) 29.05 (2.54)* 3.72 2,147 .03 .37 .51 .14 
PAL First trial memory score 15.18 (0.38) 14.05 (0.62) 13.63 (0.49) 3.00 2,147 .05 .32 .43 .12 
Declarative memory 
RAVLT Learning performance (∑ trials 1-5) 61.92 (0.89) 58.35 (1.46) 54.17 (1.15)*** 12.59 2,147 <.001 .39 .84 .46 
RAVLT Adj. recognition performance p(A) 0.875 (0.01) 0.838 (0.02) 0.833 (0.02) 1.90 2,147 .15 .31 .36 .04 
RAVLT  Delayed recall trial 7 13.13 (0.27) 12.12 (0.44) 10.96 (0.35)*** 10.78 2,147 <.001 .39 .84 .45 
PAL Total errors adjusted 11.38 (1.70) 16.67 (2.79) 18.47 (2.19) 3.17 2,147 .05 .34 .46 .12 
PAL Total trials adjusted 8.66 (0.38) 9.76 (0.61) 10.33 (0.48)* 3.46 2,147 .03 .31 .47 .16 
Executive functions 
IED Total errors adjusted 29.95 (4.41) 30.12 (7.21) 41.56 (5.67) 1.32 2,147 .27 .00 .31 .31 
IED Total trials adjusted 104.00 (7.82) 104.16 (12.79) 126.86 (10.06) 1.64 2,147 .20 .00 .35 .35 
SWM Strategy score 32.47 (0.61) 34.06 (1.00) 34.44 (0.78) 1.97 2,147 .14 .30 .38 .07 
RAVLT Recall consistency in % 91.86 (1.09) 87.29 (1.79) 84.35 (1.41)*** 8.10 2,147 <.001 .45 .74 .29 
  
 
Estimated means and standard errors. ANCOVA (all groups, corrected for age, verbal IQ, and ADHS-SR sum score). Significant p values are shown in bold. Significant Sidak post-hoc test vs. control 
group: *p<.05; **p<.01; ***p<.001. GCI and cognitive domain scores are z-transformed values.
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Table S7. Neuropsychological test scores Study 1. Cocaine user group comparison. 
  LowLevCU (n=26) 
HighLevCU 
(n=49) F df, dferr p Cohen's d 
Global Cognitive Index  -0.48 (0.12) -0.76 (0.09) 3.21 1,68 .08 .42 
Neurocognitive domain scores 
Attention -0.55 (0.18) -0.66 (0.13) .21 1,68 .65 .12 
Working memory -0.62 (0.14) -0.65 (0.10) .03 1,68 .86 .04 
Declarative memory -0.52 (0.20) -0.98 (0.14) 3.21 1,68 .08 .44 
Executive functions -0.23 (0.18) -0.74 (0.13) 5.02 1,68 .03 .55 
Neuropsychological test scores 
Attention 
RVP Discrimination performance A' 0.886 (0.01) 0.890 (0.01) .09 1,68 .76 .08 
RVP Total hits 15.35 (0.99) 15.75 (0.70) .10 1,68 .75 .08 
RAVLT Supraspan trial 1 8.65 (0.37) 7.39 (0.26) 7.15 1,68 .009 .65 
Working memory 
LNST Score 13.5 (0.53) 13.88 (0.37) .32 1,68 .57 .14 
SWM Total errors 27.53 (3.68) 30.31 (2.61) .35 1,68 .56 .15 
PAL First trial memory score 13.45 (0.68) 13.31 (0.48) .03 1,68 .87 .04 
Declarative memory 
RAVLT Learning performance (∑ trials 1-5) 59.08 (1.75) 53.04 (1.24) 7.34 1,68 .009 .63 
RAVLT Adj. recognition performance p(A) 0.839 (0.03) 0.825 (0.02) .18 1,68 .67 .11 
RAVLT  Delayed recall trial 7 12.32 (0.53) 10.67 (0.37) 6.02 1,68 .02 .61 
PAL Total errors adjusted 17.7 (3.81) 20.00 (2.69) .22 1,68 .64 .13 
PAL Total trials adjusted 9.99 (0.78) 10.76 (0.55) .60 1,68 .44 .20 
Executive functions 
IED Total errors adjusted 25.79 (8.17) 43.46 (5.79) 2.87 1,68 .09 .44 
IED Total trials adjusted 96.19 (14.35) 130.12 (10.16) 3.43 1,68 .07 .48 
SWM Strategy score 34.27 (0.97) 34.63 (0.69) .08 1,68 .77 .08 
RAVLT Recall consistency in % 87.86 (2.37) 82.86 (1.68) 2.75 1,68 .10 .41 
  
 
Estimated means and standard errors. ANCOVA (only cocaine user groups, corrected for age, verbal IQ, ADHS-SR sum score, 
abstinence duration, and cumulative lifetime dose of cocaine). Significant p values are shown in bold. GCI and cognitive domain 
scores are z-transformed values. 
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Figure S1 
 
Levamisole-cocaine-ratio frequency chart (n=75). The bold black line represents the group assignment LCR-
cutoff of 25%. 
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Figure S2 
 
Regions of interest (ROI) included in this study projected to the inflated surface of FreeSurfer’s average 
template. From these regions, cortical thickness was extracted. Left hemisphere is indicated for visualization, 
however, cortical thickness within the same ROIs were also extracted from the right hemisphere. 
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Figure S3 
 
Estimated means and standard errors in lowLevCU (n=26) and highLevCU (n=49). ANCOVA (only cocaine 
user groups, corrected for age, verbal IQ, ADHS-SR sum score, abstinence duration, and cumulative lifetime 
dose of cocaine). Significant Sidak post-hoc test: *p<.05; Cohen’s d. 
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Figure S4 
 
Pearson’s product-moment correlations between executive functions z-scores and log-transformed 
levamisole concentrations in hair (the constant 1was added because the data of two CU contained 0 values)  
in a combined CU sample (n=75, r= -.23, p<.05, one-tailed).  
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Figure S5 
 
Pearson’s product-moment correlations between the middle frontal gyrus thickness (in mm) and log-
transformed levamisole concentrations in hair (the constant 1was added because the data of one CU 
contained a 0 value)  in a combined CU sample (n=29, r= -.32, p<.05, one-tailed).  
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